HeartFlow vs SOPHiA GENETICS
HeartFlow reported revenue of $176 million in fiscal 2025, 2.3 times SOPHiA GENETICS's $77 million in fiscal 2025. HeartFlow's revenue grew 39.9% in its latest year, and SOPHiA GENETICS's grew 18.6%. HeartFlow had an operating margin of -36.4%, against -91.8% at SOPHiA GENETICS. Free cash flow was −$59 million at HeartFlow and −$36 million at SOPHiA GENETICS.
Side by side
| HeartFlow | SOPHiA GENETICS | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $176M | $77M |
| Revenue growth | 39.9% | 18.6% |
| Revenue growth a year, last 5 years | — | 22.2% |
| Gross margin | 76.8% | 67.4% |
| Operating margin | −36.4% | −91.8% |
| Net margin | −66.3% | −102.2% |
| Free cash flow | −$59M | −$36M |
| Free cash flow margin | −33.5% | −47.2% |
| Return on capital | — | −207.1% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 587.1% | 2.2% |
| Last close | $44.63 | $6.68 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $1.1 million, sold $142.3 million | bought $99,000, sold $4.2 million |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
HeartFlowSOPHiA GENETICS
Operating margin
Percent of revenue
HeartFlowSOPHiA GENETICS
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
HeartFlowSOPHiA GENETICS
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the HeartFlow and SOPHiA GENETICS pages.